KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) FCF Margin (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed FCF Margin for 16 consecutive years, with 6.74% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 1549.0% year-over-year to 6.74%, compared with a TTM value of 22.51% through Dec 2025, up 543.0%, and an annual FY2025 reading of 22.51%, up 543.0% over the prior year.
  • FCF Margin was 6.74% for Q4 2025 at Biomarin Pharmaceutical, down from 43.84% in the prior quarter.
  • Across five years, FCF Margin topped out at 43.84% in Q3 2025 and bottomed at 16.5% in Q1 2023.
  • Average FCF Margin over 5 years is 11.31%, with a median of 12.84% recorded in 2021.
  • The sharpest move saw FCF Margin skyrocketed 2921bps in 2021, then tumbled -3240bps in 2022.
  • Year by year, FCF Margin stood at 3.9% in 2021, then crashed by -38bps to 5.38% in 2022, then skyrocketed by 96bps to 0.22% in 2023, then skyrocketed by 10116bps to 22.23% in 2024, then plummeted by -70bps to 6.74% in 2025.
  • Business Quant data shows FCF Margin for BMRN at 6.74% in Q4 2025, 43.84% in Q3 2025, and 20.37% in Q2 2025.